WO2006038656A1 - アレルギー抑制剤 - Google Patents
アレルギー抑制剤 Download PDFInfo
- Publication number
- WO2006038656A1 WO2006038656A1 PCT/JP2005/018451 JP2005018451W WO2006038656A1 WO 2006038656 A1 WO2006038656 A1 WO 2006038656A1 JP 2005018451 W JP2005018451 W JP 2005018451W WO 2006038656 A1 WO2006038656 A1 WO 2006038656A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chrysin
- composition
- disease
- cells
- ige
- Prior art date
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 71
- 230000007815 allergy Effects 0.000 title claims abstract description 61
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 45
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 claims abstract description 203
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 claims abstract description 100
- 235000015838 chrysin Nutrition 0.000 claims abstract description 100
- 229940043370 chrysin Drugs 0.000 claims abstract description 100
- 102000009438 IgE Receptors Human genes 0.000 claims abstract description 68
- 108010073816 IgE Receptors Proteins 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims abstract description 61
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims abstract description 44
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims abstract description 29
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000008714 apigenin Nutrition 0.000 claims abstract description 29
- 229940117893 apigenin Drugs 0.000 claims abstract description 29
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 25
- 229960001340 histamine Drugs 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 238000012261 overproduction Methods 0.000 claims abstract description 9
- 229940119155 Histamine release inhibitor Drugs 0.000 claims abstract description 8
- 239000003301 histamine release inhibitor Substances 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 27
- 230000001164 bioregulatory effect Effects 0.000 abstract description 2
- 235000012041 food component Nutrition 0.000 abstract description 2
- 239000005428 food component Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 67
- 230000000694 effects Effects 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- 102000004388 Interleukin-4 Human genes 0.000 description 21
- 239000012528 membrane Substances 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 18
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- 210000004379 membrane Anatomy 0.000 description 18
- 210000003651 basophil Anatomy 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 230000001629 suppression Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229910019142 PO4 Inorganic materials 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000013566 allergen Substances 0.000 description 12
- 239000010452 phosphate Substances 0.000 description 12
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 description 10
- -1 quercetin glycosides Chemical class 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 9
- 230000003266 anti-allergic effect Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108010058846 Ovalbumin Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 210000003630 histaminocyte Anatomy 0.000 description 8
- 229940092253 ovalbumin Drugs 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 235000012907 honey Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 description 6
- 101710128966 High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000000043 antiallergic agent Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 101100293276 Caenorhabditis elegans cra-1 gene Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 description 4
- 101150112014 Gapdh gene Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 201000010105 allergic rhinitis Diseases 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 235000020932 food allergy Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000008105 immune reaction Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 210000003519 mature b lymphocyte Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000003405 preventing effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 244000124853 Perilla frutescens Species 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 3
- 235000009498 luteolin Nutrition 0.000 description 3
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 2
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 2
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 150000001765 catechin Chemical class 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- YQHMWTPYORBCMF-ZZXKWVIFSA-N 2',4,4',6'-tetrahydroxychalcone Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-ZZXKWVIFSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- SCZVLDHREVKTSH-UHFFFAOYSA-N 4',5,7-trihydroxy-3'-methoxyflavone Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 SCZVLDHREVKTSH-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 206010001742 Allergy to animal Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101100385324 Arabidopsis thaliana CRA1 gene Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010082169 Chemokine CCL17 Proteins 0.000 description 1
- 102000003805 Chemokine CCL19 Human genes 0.000 description 1
- 108010082161 Chemokine CCL19 Proteins 0.000 description 1
- 102000006435 Chemokine CCL21 Human genes 0.000 description 1
- 108010083702 Chemokine CCL21 Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 101150031350 Cxcl2 gene Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 101100117488 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mip-1 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101100434648 Petromyzon marinus SDS-1 gene Proteins 0.000 description 1
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 description 1
- FGUBFGWYEYFGRK-HNNXBMFYSA-N Pinocembrin Natural products Cc1cc(C)c2C(=O)C[C@H](Oc2c1)c3ccccc3 FGUBFGWYEYFGRK-HNNXBMFYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- UOSZQIQUCYTISS-UHFFFAOYSA-N chrysoeriol Natural products C1=C(O)C(C)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 UOSZQIQUCYTISS-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- QKUSRAKPUWQSJS-UHFFFAOYSA-N diazanium 3-ethyl-2H-1,3-benzothiazole-6-sulfonate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)C1=CC=C2N(CC)CSC2=C1.[O-]S(=O)(=O)C1=CC=C2N(CC)CSC2=C1 QKUSRAKPUWQSJS-UHFFFAOYSA-N 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- OLBCNYLXXLYHAI-UHFFFAOYSA-N galloylepigallocatechin Natural products C=1C(O)=C(O)C(O)=C(OC=2C(=C(O)C=C(C=2)C(=O)OC2C(OC3=C4C(O)=CC(O)=C3C2)C=2C=C(O)C(O)=C(O)C=2)O)C=1C1OC2=CC(O)=CC(O)=C2C4C1OC(=O)C1=CC(O)=C(O)C(O)=C1 OLBCNYLXXLYHAI-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 210000000350 mc(t) Anatomy 0.000 description 1
- 201000005299 metal allergy Diseases 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003000 phloroglucinols Chemical class 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- URFCJEUYXNAHFI-ZDUSSCGKSA-N pinocembrin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-ZDUSSCGKSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- FJYGFTHLNNSVPY-BBXLVSEPSA-N theaflavin digallate Chemical compound C1=C([C@@H]2[C@@H](CC3=C(O)C=C(O)C=C3O2)O)C=C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(=O)C2=C1C([C@H]1OC3=CC(O)=CC(O)=C3C[C@H]1O)=CC(O)=C2OC(=O)C1=CC(O)=C(O)C(O)=C1 FJYGFTHLNNSVPY-BBXLVSEPSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- PZYFJWVGRGEWGO-UHFFFAOYSA-N trisodium;hydrogen peroxide;trioxido(oxo)vanadium Chemical compound [Na+].[Na+].[Na+].OO.OO.OO.[O-][V]([O-])([O-])=O PZYFJWVGRGEWGO-UHFFFAOYSA-N 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an allergy inhibitor containing chrysin.
- the agent of the present invention can be in the form of foods including beverages or pharmaceuticals.
- Patent Document 1 discloses a polyphenol mixture derived from an immature fruit collected at a time when a fruit picking operation is performed.
- This fruit polyphenol mixture is a simple polyphenolic compound, which is a caffeic acid derivative, P-tamaric acid derivative, flavan-3-ols (catechins), flavonols (quercetin glycosides), dihydrochalcone. Most of its composition is occupied by condensed tannins, etc. as high molecular weight polyphenolic compounds such as phleretin glycosides. It is said to be effective as a protogenic agent, allergy inhibitor, anti-corrosion agent, and deodorant.
- Patent Document 2 describes a hyaluro-dase activity inhibitor comprising at least one substance selected from tea leaf-derived theaflavin monogalley 1 A, theaflavin monogallate B and theaflavin digallate as an active ingredient. Is disclosed. Since hyaluronan-dase has an action as an inflammatory agent, and its activity is inhibited by anti-inflammatory agents and anti-allergic agents, these active ingredients inhibit hyaluronan-dase activity and cause various inflammations. And allergies are alleviated.
- Patent Document 3 describes the separation of the polyphenol fraction of the aqueous solvent extract of tea leaves from 3-0-methylgalloepepigalocatechin and Z or 4-0-methyl.
- an antiallergic agent containing galloylepigallocatechin as an active ingredient. These catechins are said to suppress type I and type IV allergic reactions.
- Patent Document 4 discloses that stricchun that can be separated and collected from the polyphenol fraction obtained by extracting tea leaves with an aqueous solvent and the main component of its methyli-derived derivative are at least one selected polyphenol as an active ingredient.
- an antiallergic agent characterized by comprising: This active ingredient was discovered by screening using the IgE production inhibitory effect as an index.
- Patent Document 5 discloses an antiallergic agent and an antiinflammatory agent containing a phloroglucinol derivative, which is an extract component of the peel of akamegashi persimmon. This active ingredient is said to have an inhibitory effect on histamine release and an inhibitory effect on prostaglandin E2 production.
- Patent Document 6 is characterized by blending an extract of a Labiatae plant organic solvent based on the knowledge that the extract of Labiatae plant power specifically suppresses TNF production.
- An anti-allergic cosmetic composition is disclosed. This composition is said to have an immune function suppressing action, an antiallergic effect on a type I disease model, and an atopic dermatitis effect.
- Patent Document 8 discloses a histamine release inhibitor containing one or more selected from apigenin, chrysoeriol, luteolin and rosmarinic acid power derived from an alcoholic extract of perilla seed. This histamine release inhibitor makes it difficult to release histamine sensitized cells during the onset of type I allergy. Therefore, allergic diseases can be effectively treated and prevented.
- Patent Document 9 discloses an anti-allergic composition containing, as an active ingredient, an extract of the petals of Rarifunesou containing at least one compound selected from the group consisting of luteolin, apigenin and apigenin-7-0-darcoside. To do.
- This composition is said to have an effect of suppressing intenseness and itching in inflammatory and allergic skin diseases such as atopic skin disease, hay fever, food allergy, and hives.
- the active ingredient has a remarkable inhibitory effect on the itchiness induced by histamine-releasing agent from mast cells, and one of the mechanisms of the anti-stagnation action of the active ingredient is degranulation suppression. It is considered.
- Hachimi contains P-hydroxybenzoic acid, P-tamaric acid, cis, trans-abcisic acid, cinnamic acid, pinobankin, pinocembrin, chrysin, etc., and has been reported to have an anti-oxidant effect and the like.
- Non-Patent Documents 1 to 4 As for chrysin, it is known that it has an action of suppressing the action of aromatase which converts androstenedione, testosterone, etc. into estrogen, and is marketed as a supplement for improving hormone balance.
- honey is mainly related to honey allergy in relation to allergy, and studies aimed at improving symptoms include atopic properties when a mixture of honey, beeswax and olive oil is administered topically.
- Non-patent Document 5 reports that it was useful for dermatitis and psoriasis vulgaris (Non-patent Document 5), or there was no report that an anti-allergic effect was observed for specific components of honey.
- Patent Document 1 Japanese Patent Laid-Open No. 7-285876 (Japanese Patent No. 3521155) or Japanese Patent Laid-Open No. 2002-47196
- Patent Document 2 Japanese Patent No. 3242997
- Patent Document 3 Japanese Patent Laid-Open No. 2000-159670
- Patent Document 4 JP 2002-12545
- Patent Document 5 JP 2003-73265 A
- Patent Document 6 Japanese Patent Laid-Open No. 6-293652
- Patent Document 7 Japanese Patent Laid-Open No. 9-20672 (Patent No. 3071669)
- Patent Document 8 JP 2000-86510 A
- Patent Document 9 Japanese Patent Laid-Open No. 2001-278796
- Non-patent literature l Nele Gheldof et al: J. Agric. Food Chem. 2002, 50, 5870-5877
- Non-patent literature 2 Jed W. Fahey et al: J. Agric. Food Chem. 2002, 50, 7472-7476
- Non-Patent Document 3 Lihu Yao et al: J. Agric. Food Chem. 2004, 52, 210-214
- Non-Patent Document 4 Jed W. Fahey et al: J. Agric. Food Chem. 2004, 52, 7472-7476
- Non-Patent Document 5 AFWaili NS .: Complement Ther Med. 2003 Dec; 11 (4): 226-34 Summary of the Invention
- the present inventor has conducted research on the bioregulatory function of food ingredients. As a result of finding that honey has an antiallergic effect and conducting further detailed studies, the inventors have identified an effective ingredient, taricin, as an antiallergic agent, and completed the present invention.
- FIG. 1 shows the inhibitory effect of chrysin on IgE heavy chain embryonic transcription ( ⁇ GT).
- Human mature B cell line DND39 cells were supplemented with IL-4 (25 U / ml) and various concentrations of chrysin and cultured for 48 hours. MRNA was collected from the cells, cDNA was synthesized, and the products amplified by RT-PCR were separated by agarose gel electrophoresis and transferred to a membrane to detect ⁇ GT.
- GAPDH Denricel aldehyde-3-phosphate dehydrogenase
- FIG. 2 shows the inhibitory effect of chrysin on STAT6 phosphate.
- FIG. 3 shows a decrease in high affinity IgE receptor (Fc ⁇ RI) expression by chrysin.
- Anti-human Fc (RI antibody (CRA1) was used to analyze the expression level of Fc ⁇ RI on the surface of the human basophil-like cell line KU812 by flow cytometry. The percentage of Fc ⁇ RI strongly expressing cells was expressed in%.
- FIG. 4 shows the relationship between the expression of proteins constituting the high affinity IgE receptor (Fc ⁇ RI). Shows the inhibitory effect of syn. Fc ⁇ RI and ⁇ chain protein expression is collected by lysing cells cultured with the addition of chrysin, immunoprecipitated with antibody, and immunoprecipitates blotted after SDS-PAGE Detected. j8 -actin as control
- FIG. 5 shows the inhibitory effect of talysin on mRNA transcription of high affinity IgE receptor (Fc ⁇ RI) constituent proteins.
- Fc ⁇ RI high affinity IgE receptor
- FIG. 6 shows the phosphate inhibitory effect of STAT6 administered orally by chrysin.
- Spleen lymphocytes collected from the spleen of mice that were orally dosed with chrysin were stimulated with LPS or LPS + IL-4 (500 U / mL), and then phosphorylated by immunoprecipitation using an anti-STAT6 antibody and immunoblot method. Oxidation STAT6 was detected.
- FIG. 7 shows the effect of a clinicon on the mRNA expression level of the Fc ⁇ RI constituent chain of human peripheral blood basophils.
- Peripheral blood basophils (1 X 10 6 cells / mL) collected from donor veins are cultured for 24 hours in a medium supplemented with 25 M chrysin or dimethyl sulfoxide (DMSO), and then RNA is extracted.
- DMSO dimethyl sulfoxide
- FIG. 8 shows the effect of chrysin on histamine release from human basophils.
- Human basophil basal cell line KU812 cells (5 X 10 5 cells / mL) added with 25 ⁇ chrysin 1 mM CaCl-containing T
- the present invention provides an allergy inhibitor, particularly a type I allergy inhibitor, containing chrysin.
- Chrysin (5, 7-dihydroxyflavone) has the following structure.
- the chrysin used in the present invention can be prepared from natural products containing chrysin, such as honey, carrot seeds, and certain kinds of oaks.
- allergy is used in the usual sense in the field of the present invention except in special cases. That is, “allergy” as used herein can be defined as systemic or local injury to a living body based on an immune reaction, except in special cases. This includes allergies based on humoral immune responses caused by antibodies in blood (types 1, II and III) and allergies based on cellular immunity caused by sensitized lymphocytes (type IV allergies).
- Allergy or “allergic disease” includes atopic dermatitis, hay fever, allergic rhinitis, allergic conjunctivitis, bronchial asthma, hives, collagen disease, hypersensitivity pneumonitis, anaphylaxis, food allergy, drug allergy, tick Includes allergies, metal allergies, and animal allergies.
- the mechanism of allergic diseases is as follows: (1) contact between allergens and immunocompetent cells (antigen-presenting cells), (2) antigen-presenting cells, T (3) Activation of effector cells by antigen-antibody reaction, (4) Release of chemical mediators such as histamine from Fecta cells, cytoforce in, etc. (5) In organs Proceed in the order of the appearance of allergic reactions. Cellular immune responses also include (1) sensitization of sputum cells with antigens, (2) binding of sensitized sputum cells to antigens, (3) production of cytokines and chemokines from sensitized sputum cells, Proceeding in the order of the activity of other cells and the generation of further site force in, (4) Appearance of allergic reaction in organs. Regardless of which stage is adjusted, so long as chrysin is used for allergy suppression, it is included in the range of the allergy suppressing agent containing chrysin of the present invention.
- chrysin caused allergy based on humoral immune reaction.
- Early stages of the reaction specifically, by chrysin, at least IL-4 induced IgE heavy chain embryonic transcription stage, STAT6 phosphate stage, high affinity IgE receptor expression stage on the cell surface, It turned out that the a-chain or ⁇ -chain expression stage constituting the high-affinity IgE receptor and the transcription stage of the high-affinity IgE receptor can be regulated. Therefore, the allergy-suppressing agent of the present invention can be effectively used especially for allergies based on humoral immune reactions (types 1, II and III allergies), especially for type I allergies. Furthermore, chrysin can be used as an effective component of a histamine release inhibitor, and can also be used effectively for the treatment of various diseases or conditions for which any of the above-described steps is effective.
- the present invention also provides the following:
- Histamine release inhibitors including chrysin
- Threads and adults containing chrysin for treating diseases or conditions associated with IgE production (more specifically, diseases or conditions associated with IL-4 induced IgE heavy chain embryonic transcription).
- a composition comprising chrysin for treating a disease or condition associated with a high affinity IgE receptor (more specifically, a disease or condition associated with a high affinity IgE receptor on the cell surface) To treat diseases or conditions related to oc chain or ⁇ chain constituting high affinity IgE receptor and to treat diseases or conditions related to transcription of high affinity IgE receptor Thread) and composites; and
- composition for treating a disease or condition associated with overproduction of IL-4 wherein the composition is a yarn composition containing chrysin.
- the allergy when the allergy is referred to as “suppressing” and the term “treating” a certain disease or condition, it relates to the allergy or the composition thereof. It means prevention or treatment of a disease or condition (hereinafter simply referred to as “allergy”), mild suppression of allergy, or suppression of progression of allergy. “Suppression” and “treatment” include coping therapy that suppresses symptoms and fundamental therapies such as reducing hypersensitivity or improving constitution, and immediate and long-term prevention and Z or treatment. In addition, after allergies appear, new related symptoms are predicted after that. Includes preventing.
- the agent or composition of the present invention can be appropriately used depending on the subject, the state of the disease, the purpose, etc. in order to suppress or treat allergies and the like. Because of the inhibitory action of chrysin on IgE production, the agent or composition of the present invention can be expected to have allergy and other preventive effects and long-term therapeutic effects. Therefore, when used for such purposes, the agent or composition of the present invention It may be preferable to use the composition continuously before, during or at the onset of allergies.
- the agent or composition of the present invention can be expected to have an immediate allergy suppressing effect and a long-term allergy preventing effect.
- the agent or composition of the present invention can be used at the onset or after the onset of allergy or the like. In this case, the agent or composition of the present invention can exert the action of preventing the onset of new allergies and the like thereafter.
- the agent or composition of the present invention can be used continuously before or at a low time such as allergy.
- the expression of high-affinity IgE receptor can always be maintained at a low level in the subject, and the sensitivity of the subject to allergen can be expected to decrease.
- the term “continuous” relates to the method of using the agent or composition of the present invention
- the term “continuous” means that it is used more than once in a certain period (eg, several days, weeks, months, years).
- a certain period eg, several days, weeks, months, years.
- chrysin can exert an inhibitory effect on IL-4-induced STAT6 phosphate even when used at discontinuously low doses (see Example 3). .
- Agent or composition may be in the form of a medicament.
- chrysin is capable of exerting an inhibitory effect on IL-4-induced STAT6 phosphate even when used at discontinuously low doses. Therefore, the agent or composition of the present invention Things can be taken relatively freely. Therefore, the agent or composition of the present invention can be in a form other than medicine (for example, food or beverage).
- the agent or thread of the present invention has a specific use (for example, for prevention, for improving hypersensitivity to allergens, for improving constitution, for long-term treatment, etc.).
- to inhibit histamine release to suppress IgE production, to suppress IL-4 induced IgE heavy chain embryonic transcription, to suppress STAT6 phosphate, and to express high affinity IgE receptor.
- To suppress the expression of high affinity IgE receptor on the cell surface to suppress the expression of ex chain or ⁇ chain constituting high affinity IgE receptor, to suppress the expression of high affinity IgE receptor Etc.), and Z or its specific usage (eg quantity, number of times, continuous use, duration, etc.) can be displayed.
- the agent or composition of the present invention is a pharmaceutical
- the amount of chrysin as an active ingredient can be appropriately determined according to the purpose, symptom, age of the subject, weight, etc. It can be formulated so that it can be administered in an amount of about 0.001 to 1000 mg / kg, preferably about 0.01 to 100 mg / kg, once to several times a day.
- the antiallergic agent is effective when taken orally at an amount of 1.68 g / day or more (when the average weight of an adult male is 60 kg) as chrysin.
- the agent or composition of the present invention may be an agent or composition that enables oral administration or ingestion of about 1.68 g or more of chrysin per day.
- it can be an agent or composition containing 1.68 g or more chrysin in the daily oral dose or intake, and 28 mg in the daily oral dose or intake.
- an antiallergic oral formulation administered three times a day can contain 560 mg or more of chrysin per dose.
- foods with antiallergic functions including beverages
- foods with antiallergic functions that are recommended to be ingested about 3 a day can be foods containing 560 mg or more of chrysin.
- the administration route and dosage form can also be appropriately designed.
- it can be formulated for systemic administration or for local administration, and is used as an internal preparation, external preparation, solid preparation, liquid preparation. , Powders, granules, capsules, tablets, ointments, plasters, haps, lotions, liniments, or suppositories.
- it can also be set as a sustained release formulation and a controlled release formulation.
- the preparation can be carried out according to conventional methods, and various pharmaceutically acceptable additives such as excipients, binders, disintegrants, lubricants, coating agents, suspending agents, emulsifiers. Stabilizers, preservatives, and buffering agents can be used.
- the agent or composition of the present invention can be in the form of a medical device or a quasi-drug. In addition, it can be used with ointment, lotion, lotion, soap, shampoo, wet tissue, etc.
- the agent or composition of the present invention may be in the form of a cosmetic, food or beverage.
- the amount of chrysin as an active ingredient can be appropriately determined according to the case of a pharmaceutical product.
- Foods or beverages containing the allergy inhibitor of the present invention can be made into functional nutrition foods, foods for specified health use, health foods, nutritional supplements, instant foods, frozen foods, drinks, etc.
- confectionery confectionery, rice cakes, soups, seasonings (mayonnaise, miso, soy sauce, dressing, sauce, etc.), other fermented foods, canned foods, animal foods (ham and sausages, etc.), milk It can be in the form of products (yogurt, etc.), pickles, soft drinks, carbonated drinks, fruit drinks, milk drinks, lactic acid drinks, sports drinks, etc.
- the present invention also provides the following.
- a method for treating a disease or condition associated with said method comprising administering to a mammal in need of such treatment a therapeutically effective amount of krysin.
- chrysin is used in combination with apigenin. That is, the present invention provides a pharmaceutical or food composition containing chrysin and apigenin.
- Apigenin has the following structure.
- Example 1 Inhibition of IgE production (inhibition of IgE heavy chain embryonic transcription ( ⁇ GT) and inhibition of STAT6 phosphorylation)>
- IgE-type antibodies play an important role in the development of type I allergies.
- IgE produced by B cells binds to high affinity IgE receptors present on the cell membranes of mast cells and basophils.
- mediators such as histamine are released, leading to the development of allergies.
- IgE is a type of immunoglobulin and a biomolecule that is key to the development of immediate allergy. IgE production in healthy human serum (300 ng / ml) is negligible compared to IgG (15 mg / ml), the same immunoglobulin, but overproduction is observed in allergic patients, and overproduction of IgE Is considered one of the causes of various allergic diseases including hay fever and food allergies.
- IgE produced by sensitization to allergens to bind to high-affinity IgE receptors present on the surface of mast cells and basophils
- allergens that re-enter under this state bind to IgE IgE
- calcium is mobilized into the cell, a signal transduction mechanism through the cell membrane is activated, the cell is activated and degranulates, and histamine, eosinophil migration factor and favorable Pharmacologically active substances such as neutrophil migration factor are released.
- the arachidonic acid cascade in the cell membrane is also activated, producing and secreting lipid mediators such as leukotrienes prostaglandins and thromboxanes, and cytosines such as interleukins, which cause immediate allergies.
- Inhibiting IgE production which plays a very important role in the development of allergies in this way, is in terms of preventing and treating allergies! It is very effective.
- the heavy chain constant region is an important region for expressing the biological activity of immunoglobulin (cell binding and complement binding ability).
- B cells Immediately after being separated into mature B cells, B cells produce Ig M-type immunoglobulin molecules. Subsequently, B cells activated to a state capable of responding to site force-in change the sequence of the variable region of the heavy chain in response to stimulation of site force-in. Recombines genes into other classes of heavy chain constant regions that are not allowed to pass. This phenomenon is called a class switch, and IgE-type antibodies are also produced only by this recombination. In the IgE class switch, prior to DNA recombination, the primary transcript that reaches the I region force constant region upstream of the IgE heavy chain constant region (C ⁇ ) is transcribed, and splicing results in a germline transcript that becomes the I region and C ⁇ force.
- C ⁇ I region force constant region upstream of the IgE heavy chain constant region
- ⁇ GT IgM heavy chain constant region
- This cyto force-in binds to each receptor expressed on the membrane surface of B cells, and by cross-linking the receptor, JAK kinase binding to the cytoplasmic side of the receptor is mutually phosphorylated and activated. Activated JAK tyrosine phosphorylates the receptor, where the transcription factor STAT6 binds to this tyrosin phosphorylated residue.
- STAT6 associated with the receptor is phosphorylated by JAK, phosphorylated STAT6 forms a homodimer, moves into the nucleus, binds to the promoter region of germline C ⁇ , and induces ⁇ GT expression.
- Chrysin was purchased from Sigma Chemical Co. (St. Louis, MO). Chrysin was dissolved in dimethyl sulf oxide (DMSO) and diluted with ethanol to 10% DMSO.
- DMSO dimethyl sulf oxide
- RPMI 1640 medium (Nissui) supplemented with 5% FBS (Intergen) at 37 ° C under 5% CO with water vapor saturation.
- RPMI 1640 medium is 100 U / m
- DND39 cells were adjusted to 2 ⁇ 10 5 cells / mL and cultured for 48 hours in the presence of IL-4 (25 U / mL) and each concentration of chrysin.
- the cell culture solution not exceeding 1 X 10 7 cells was collected in a 15 mL polypropylene centrifuge tube, centrifuged at 300 X g, the supernatant was removed, and the cells were washed once with PBS. The cells after centrifugation and removal of the supernatant were stored on ice until the next operation to minimize RNA degradation by RNase.
- 1 mL of TrizoKlnvitrogen, Carlxbad, CA) was added and suspended well by pipetting until no lumps were seen.
- the suspension was transferred to a 1.5 mL tube, and the tube was allowed to stand for 5 minutes.
- 200 / z L of black mouth form (Wako Pure Chemical Industries, Ltd.) was added, stirred vigorously, allowed to stand at room temperature for 3 minutes, and then centrifuged at 12.000 X g for 15 minutes.
- 450 L of the upper layer was transferred to another 1.5 mL tube, 500 L of isopropanol (Wako Pure Chemical Industries) was added and stirred vigorously, and then allowed to stand at room temperature for 10 minutes.
- RNA concentration was measured using a spectrophotometer Ultrospec 3000 (Pharmacia Biotech, Piscataway, NJ).
- PCR was performed using 0.5 U Taq DNA polymerase (Fermentas) in a volume of 10 ⁇ L.
- the reagents contained in the PCR reaction solution are as follows.
- Taq DNA polymerase (0.1 ⁇ L), 20 ⁇ sense primer (0.5 ⁇ L),
- sequences of the primers used for PCR are as follows.
- G3PDH-F 5'-gCT Cag ACA CCA Tgg ggA Agg T-3 ',
- G3PDH-R 5'-gTg gTg Cag gAg gCA TTg CTg A-3 '.
- Transferred membrane is random buffer (Composition: 5 X SSC (SSC; 0.3M Sodium citrate, 3M NaCl, pH7.0) 3 M NaCl, 3 33 mM CHO Na ⁇ 2 ⁇ 0, 0.1% SDS ⁇ 5% (w / v) Dextran sulfate sodium salt)
- bufferA composition: 100 mM Tris-HC1 pH 9.5, 300 mM NaCl
- dilute the antibody blocking agent (Amersham # 1059304) 10-fold with 1 x bufferA. Hold 3 mL and shake at room temperature for 2 hours to perform blocking. 5 mL of alkaline phosphatase-labeled anti-fluorescein antibody diluted 5000-fold with% BSA-bufferA was added and reacted with the antibody by shaking at room temperature for 1 hour. After completion of the antibody reaction, the membrane was washed with 0.67% Tween-buffer A at room temperature for 3 times with shaking for 20 minutes, and finally washed lightly with buffer A. This film was sandwiched between vinyl sheets, CDP-Star was sprinkled evenly at 200 L per film, and left at room temperature for 1 minute, and then ⁇ GT was detected with an image analyzer.
- DND39 cells were adjusted to 2 ⁇ 10 6 cells / mL, IL-4 (100 U / ml) and each concentration of chrysin were added, and the cells were treated for 30 minutes to lyse the cells.
- Cell lysate was immunoprecipitated with anti-STAT6 antibody, immunoprecipitate was subjected to 8% SDS-PAGE, blotted on nitrocellulose membrane, and phosphorylated STAT6 detected with anti-tyrosine phosphate antibody (PY20) did.
- Chrysin suppressed the expression of ⁇ GT in a concentration-dependent manner and also suppressed phosphorylation of S TAT6. Chrysin was found to fundamentally suppress IgE production by inhibiting ⁇ GT expression at the level of phosphorylation of STAT6.
- IgE-type antibodies play an important role in the development of immediate allergies.
- IgE produced by B cells binds to high affinity IgE receptors present on the cell membranes of mast cells and basophils.
- mediators such as histamine and leukotriene are released, leading to the development of allergies.
- Fc ⁇ RI is a key molecule in the onset of allergic reaction involving IgE. It activates mast cells and basophils expressing Fc ⁇ RI via an antigen / antibody complex. Yes Drive signal.
- the activity of Fc ⁇ RI is caused by the aggregation of Fc ⁇ RI.
- IgE bound to Fc ⁇ RI is cross-linked by a multivalent antigen, etc., and Fc ⁇ RI aggregates to activate the signal transduction mechanism.
- KU812 cells known as human basophil cell lines, are inflammatory substance histamine-producing cells and express the high affinity IgE receptor Fc ⁇ RI on the cell surface. Therefore, the effect of chrysin on Fc ⁇ RI expression was examined using these KU812 cells.
- a medium supplemented with mM HEPES (Wako Pure Chemical Industries) was used as a basic medium.
- Fetal bovine serum (FBS) was purchased from Bio Source Internationa, and added to the basic medium so that the concentration was 5 to 10%.
- the human basophil-like cell line KU812 used in this experiment was distributed by the Japan Collection of Research Bioresources (JCRB), and was 37 (C, 5% carbon dioxide in RPMI 1640 medium supplemented with 5-10% FBS. Passaged and maintained under humidification.
- KU812 cells (1 ⁇ 10 6 cells / mL) were cultured in RPMI 1640 medium supplemented with chrysin dissolved in DMSO for 0-24 hours. A system in which only DMSO was added and cultured was used as a control. After culturing, the cells were collected, and 4 (C, 4) in 5% FBS-PBS supplemented with anti-human Fc ⁇ RI ⁇ -chain mouse monoclonal antibody CRA-1 (Kyokuto Pharmaceutical) to a concentration of 10 ⁇ g / mL.
- mouse control IgG2b antibody (DAK 0) was used at 10 g / mL as a negative control, then washed once with ice-cold PBS and labeled with anti-mouse IgG2b FITC Antibody (Protos Immunoresearch) was incubated in 5% FBS-PBS supplemented to 10 g / mL for 4 (C, 40-60 min.
- KU812 cells (1 ⁇ 10 6 cells / mL) were subjected to serum-free culture for 6 hours in RPMI 1640 medium supplemented with chrysin. After culturing, the cells were washed once with PBS, then lysed buffer (Composition : 50 mM Tris-HCl pH 7.5, 1% Triton X-100, 150 mM NaCl, ImM EDTA, 50 mM NaF, 30 mM Na PO, ImMPMSF ⁇ 2 ⁇ g / Save mL aprotinin ⁇ ImM pervanadate), 4 (30 minutes in C)
- Lysis buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X
- Protein A bepharose beads (Amersham Pharmacia Biotech) supplemented with CRA-1 antibody to a final concentration of 1 ⁇ g / mL.
- Fc ⁇ RI a chain SDS-PAGE was performed by applying the immunoprecipitation sample to 10% polyacrylamide gel and applying the cell lysis sample to 15% polyacryl amide gel for Fc ⁇ Rly chain.
- the gel was subjected to electroblotting at 100 V (60 minutes for the a chain and 30 minutes for the ⁇ chain) to transfer the protein to the -trocellulose membrane.
- the membrane was shaken with 0.05% Tween 20-TBS (TTBS) supplemented with skim milk to a final concentration of 2%, and a blocking reaction was performed at room temperature for 30-60 minutes.
- TTBS Tween 20-TBS
- KU812 cells (1 ⁇ 10 6 cells / mL) were serum-free cultured for 6 hours in RPMI 1640 medium supplemented with chrysin. After culturing, the cells were washed once with PBS, and then ImL of TrizoKln vitrogen) was added to 1 ⁇ 10 7 cells and rapidly suspended to completely lyse. After standing at room temperature for 5 minutes, 0.2 mL of Chloroform was added and stirred vigorously by inversion. After standing at room temperature for 3 minutes, centrifuge at 12,000 xg, 4 (C for 15 minutes, collect 450 / zL of the supernatant, add 0.5 mL of 2-Propanol, stir vigorously, and stir vigorously at room temperature for 10 minutes.
- Human Fe RI RI chain sense primer 5′—CTTAGGATGTGGGTTCAGAAGT—3 ′
- antisense primer 5′—GACAGTGGAGAATACAAATGTCA—3 ′.
- Human Fe RI ⁇ chain sense primer 5′—TAGGGCCAGCTGGTGTTAATGGCA—3 ′
- antisense primer 5′—GATGATTCCAGCAGTGGTCTTGCT—3 ′.
- Human G3PDH sense primer 5'—GCTCAGACACCATGGGGAAGGT—3 ′
- Antisense primer 5'—GTGGTGCAGGAGGCATTGCTGA—3 ′.
- PCR reaction solution was cDNA 1 ⁇ L, 2 mM dNTP 0.8 ⁇ L, MgCl 0.6 ⁇ 20 ⁇ U
- the electrophoresed gel was shaken in a 0.5 N NaOH solution containing 9% NaCl for 1 hour at room temperature, and then the DNA was hyphenated with 0.4 N NaOH for 5 hours or more by hygienic blotting. -Blotted to N + membrane. The membrane after blotting was washed with 2 x Saline sodium citrate (SSC; 0.3 M Sodium citrate, 3 M NaCl, pH 7.0). Probes for Fc ⁇ RI ⁇ , y chain and G 3PDH were prepared by the random labeling method.
- the target DNA amplified by RT-PCR is subcloned, the base sequence is analyzed by a DNA sequencer, and the subcloned DNA is specific to Fc ⁇ RI ⁇ , ⁇ chain and G3PDH, respectively. It was confirmed.
- PCR was carried out using these DNAs as saddles and specific primers, and the amplification products were labeled using the Gene Images random labeling module according to the attached protocol.
- the membrane on which the PCR product was blotted was immersed in the prehybridization buffer attached to the Gene Image random labeling module, shaken at 60 ° C for 60 minutes, and then washed with the prehybridization buffer. Diluted 1000 times The probe solution was exchanged and incubated at 60 ° C.
- the membrane was then washed in 0.1% SDS-1 X SSC at 60 ° C for 20 minutes, in 0.1% SDS-0.4 x SSC at 60 ° C for 20 minutes, in 0.1% SDS-0.2x SSC at 60 ° C. Washing was performed in the order of 20 minutes.
- the membrane was washed once with buffer A attached to the CDP-Star detection module kit (Amersham Pharmacia Biotech), and then the membrane was shaken in the blocking solution attached to the kit at room temperature for 1 hour.
- Samples were administered once every two days for 2 weeks to 5-week-old C57BL / 6N male mice that had been pre-fed (MF diet) for 1 week. (Total 7 doses. Total dose is 0.56 mg (28 mg / kg) per animal.)
- Example 4 Effect of chrysin on Fc ⁇ RI mRNA expression in human peripheral blood basophils>
- Venous blood was collected from the forearm of the donor's forearm, and peripheral blood lymphocytes were separated and purified by Lymphocyte Separation Medium (ICN Biomedical Inc.), and peripheral blood basophils were separated and purified by Percoll (Amersham Biosciences) density gradient centrifugation.
- Basophils (1 X 10 6 cells / mL) were cultured in 5% FCS-RPMI 1640 medium supplemented with 25 M Talysin or the solvent dimethyl sulfoxide (DMSO) for 24 hours. After extraction, the mRNA expression levels of Fc ⁇ RI ⁇ and ⁇ chains were examined by RT-PCR as in Example 1.
- Example 5 Effect of chrysin on histamine release from human basophils>
- Human basophil cell line KU812 cells (5 X 10 5 cells / mL) added with 25 ⁇ chrysin 1 mM Ca CI-containing Tyrode buffer (137 mM NaCl, 2.7 mM KC1, 1.8 mM CaCl, 1.1 mM MgCl, 1
- Intensity was measured using a fluorometer RF-1500 at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm.
- Chrysin significantly reduced histamine release induced by A23187. Chrysin inhibits the release of the inflammatory substance histamine induced by antigen stimulation.
- mice Eight-week-old BALB / c male mice were divided into AIN-93M fed group (Control group) and 0.025% chrysin-added AIN-9 3M fed group. Was fed for 2 weeks. Each animal was fed at 5 g / day and bred with free drinking water.
- OVA sensitization was performed using 100 ⁇ g OVA / aluminum hydroxide gel one week after the start of each diet.
- Reagents used in ELISA for antibody amount measurement are as follows. For blocking, PBS containing 1% bovine serum albumin (Roche) (BSA-PBS) was used. For solid phase antibodies, F (ab ') 2 go at anti-mouse (Zymed Laboratries, Incj, F (ab ') 2 rabbit anti-mouse IgM antibody (Zymed Laboratries, Inc.), rabbit anti-mouse IgA (Zymed Laboratries, Inc.) were used.
- Labeled F (ab ') 2 goat anti-mouse IgG (H (L) antibody (Zymed Laboratries, Inc.), HRP labeled rabbit anti-mouse IgM antibody (Zymed Laboratries, Inc.), H RP labeled goat anti-mouse IgA antibody (Zymed Laboratries, Inc.) was used.
- the 2,2'-Anizo-bis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (AB TS) used was purchased from Wako Pure Chemicals, and oxalic acid was purchased from Nacalai tesque (Kyoto, Japan).
- a solid-phase antibody solution (1000-fold diluted with 50 mM carbonate buffer) was dispensed onto an immunoplate at 100 ⁇ L / well and allowed to stand at 4 ° C. After washing 3 times with PBS containing 0.1% polyoxyethylene sorbitan monolaurate (Nacalai tesque) (TPBS), BSA-PBS was dispensed at 300 ⁇ L / well and incubated at 37 ° C. for 2 hours. After washing 3 times with TPBS, the sample and standard solution were appropriately diluted with BSA-PBS, added at 50 ⁇ L / well, and allowed to stand at 4 ° C for 4 minutes.
- PBS containing 0.1% polyoxyethylene sorbitan monolaurate Nacalai tesque
- a secondary antibody diluted solution (diluted 2000 times with BSA-PBS) was dispensed at 100 L / well and incubated at 37 ° C for 1 hour.
- chromogenic substrate solution is dispensed at 100 L / well, color is developed, 1.5% oxalic acid solution is dispensed at 100 ⁇ L / well to stop the reaction, and absorbance at 415-490 nm was measured.
- IgG (mg / mL) 27.7 Sat 2.4 23.5 ⁇ 3.0
- IgA (mg / mL) 0.6 ⁇ 0.1 0.6 ⁇ 0.0
- IgE (ng / mL) 87.5 ⁇ 6.9 68.2 ⁇ 4.2 * [0084] The effects of chrysin feeding on the blood IgM, IgG, and IgA levels at the end of feeding were not observed. In contrast, blood IgE levels were significantly lower in the kricin group than in the control group, and it was shown that feeding chrysin suppressed the increase in blood IgE level due to OVA sensitization. .
- Blood was collected in the same manner as in Example 6, and 32 types of serum (6Ckine, CTACK, Eotaxin, G-CSF, GM-CSF, IL-2, IL-3, IL-4, IL-5, IL-6, IL- 9, IL- 10, IL— 12, IL- 12p70, IL— 13, I- 17, IFN- y, KC, Leptin, MCP- 1, MCP- 5, MIP- 1 a, MIP- 2, MIP-3 ⁇ , RANTES, SCF, sTNFRI, TARC, TIMP—1, TNF-a, Tpo, and VEGF) were detected using Ray Bio TM Mouse Cytokine Array (Ray Biotech, In).
- CTACK cutaneous T-ceU- attracting che mokine
- G-CSF granulocyte colony-stimulating factor
- GM-CSF granulocyte—macrophage colony-stimulating factor
- IFN interferon
- KC CXC ligand 1
- MCP monocy te chemoattractant protein
- MIP macrophage inflammatory protein
- RANTES regulated upon activation normal T cell expressed and secreted
- S and F stem cell factor
- s TNFR soluble tumor necrosis TARC, thymus and activation—regula ted chemokine
- TIMP tissue inhibitor of metalloprotease
- TNF tumor necrosis factor
- Tpo thrombopoietin
- VEGF vascular endothelial growth factor.
- KU812 cells (5 X 10 5 cells / mL) were purchased from chrysin (0, 1, 5, 10 M) and apigenin (purchased from Aldrich Chem. Co. (St. Louis, MO)) (0, 1, 5, The cells were cultured for 24 hours in RPMI 1640 medium containing 5% sushi fetal serum supplemented with 10 M). After culturing, the cell surface Fc ⁇ RI expression level was measured by flow cytometric analysis (see 0047 for the experimental method).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006539318A JPWO2006038656A1 (ja) | 2004-10-05 | 2005-10-05 | アレルギー抑制剤 |
US11/664,622 US20080262080A1 (en) | 2004-10-05 | 2005-10-05 | Allergy Suppressive Agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004292500 | 2004-10-05 | ||
JP2004-292500 | 2004-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006038656A1 true WO2006038656A1 (ja) | 2006-04-13 |
Family
ID=36142728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/018451 WO2006038656A1 (ja) | 2004-10-05 | 2005-10-05 | アレルギー抑制剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20080262080A1 (ja) |
JP (1) | JPWO2006038656A1 (ja) |
WO (1) | WO2006038656A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505800A (ja) * | 2006-10-06 | 2010-02-25 | ラボラトワール クラランス | 脂性肌をケアするための化粧品組成物の使用 |
WO2015129525A1 (ja) * | 2014-02-28 | 2015-09-03 | 株式会社Aob慧央グループ | ヒアルロン酸合成促進剤、HAS2mRNA発現促進剤、ヒアルロン酸合成促進作用を有する医薬品、食品又は化粧料、及び、HAS2mRNA発現促進作用を有する医薬品、食品又は化粧料 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090276436A1 (en) * | 2008-04-30 | 2009-11-05 | Nokia Corporation | Method, apparatus, and computer program product for providing service invitations |
WO2013155476A1 (en) * | 2012-04-12 | 2013-10-17 | Integrative Enzymatics, Inc. | Composition and method for modulating inflammatory molecules with amylase |
CN111166739B (zh) * | 2020-02-18 | 2021-04-20 | 西安交通大学 | 柯因在制备抗类过敏药物中的应用 |
JP2023524312A (ja) * | 2020-05-08 | 2023-06-09 | グレータルズ オーストラリア プロプライアタリー リミテッド | 線維化疾患及び炎症性疾患の予防及び治療のための組成物及び方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118151A (ja) * | 1993-10-21 | 1995-05-09 | Kureha Chem Ind Co Ltd | アトピー性皮膚炎治療剤 |
JPH10510803A (ja) * | 1994-12-13 | 1998-10-20 | バイヤースドルフ・アクチエンゲゼルシヤフト | 化粧品及び皮膚科学的調製物中への、免疫調節剤又は免疫保護剤としてのフラボノイドの使用 |
JP2000086510A (ja) * | 1998-09-16 | 2000-03-28 | Oriza Yuka Kk | ヒスタミン遊離抑制剤 |
JP2001114686A (ja) * | 1999-10-15 | 2001-04-24 | Sunstar Inc | Th2サイトカイン発現抑制剤 |
JP2004161664A (ja) * | 2002-11-13 | 2004-06-10 | Fancl Corp | プロポリス組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2128293C (en) * | 1993-12-06 | 2002-09-03 | Masayuki Tanabe | Fruit polyphenols and medicinal compositions containing them |
JP3694733B2 (ja) * | 2000-06-29 | 2005-09-14 | 独立行政法人農業・生物系特定産業技術研究機構 | 抗アレルギー剤 |
-
2005
- 2005-10-05 JP JP2006539318A patent/JPWO2006038656A1/ja active Pending
- 2005-10-05 US US11/664,622 patent/US20080262080A1/en not_active Abandoned
- 2005-10-05 WO PCT/JP2005/018451 patent/WO2006038656A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118151A (ja) * | 1993-10-21 | 1995-05-09 | Kureha Chem Ind Co Ltd | アトピー性皮膚炎治療剤 |
JPH10510803A (ja) * | 1994-12-13 | 1998-10-20 | バイヤースドルフ・アクチエンゲゼルシヤフト | 化粧品及び皮膚科学的調製物中への、免疫調節剤又は免疫保護剤としてのフラボノイドの使用 |
JP2000086510A (ja) * | 1998-09-16 | 2000-03-28 | Oriza Yuka Kk | ヒスタミン遊離抑制剤 |
JP2001114686A (ja) * | 1999-10-15 | 2001-04-24 | Sunstar Inc | Th2サイトカイン発現抑制剤 |
JP2004161664A (ja) * | 2002-11-13 | 2004-06-10 | Fancl Corp | プロポリス組成物 |
Non-Patent Citations (4)
Title |
---|
CHEONG H ET AL: "Studies of structure activity relationship of flavonoids for the anti-allergic actions.", ARCH PHARM RES., vol. 21, no. 4, 1998, pages 478 - 480, XP002994940 * |
MASTUDA H ET AL: "Structural requirements of flavonoids for inhibition of antigen-Induced degranulation, TNF-alpha and IL-4 production from RBL-2H3 cells.", BIOORG & MED CHEM., vol. 10, no. 10, 2002, pages 3123 - 3128, XP002994939 * |
PEARCE F ET AL: "Mucosal mast cells. III. Effect of quercetin and other flavonoids on antigen-induced histamine secretion from rat intestinal mast cells.", J ALLERGY CLIN IMMUNOL., vol. 73, no. 6, 1984, pages 819 - 823, XP002994938 * |
YANO S ET AL: "Flavones Suppress the Expression of the High-Affinity IgE Receptor Fc epsilon RIin Human Basophilic KU812 Cells.", J AGRIC FOOD CHEM., vol. 53, no. 5, 2005, pages 1812 - 1817, XP002994941 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505800A (ja) * | 2006-10-06 | 2010-02-25 | ラボラトワール クラランス | 脂性肌をケアするための化粧品組成物の使用 |
WO2015129525A1 (ja) * | 2014-02-28 | 2015-09-03 | 株式会社Aob慧央グループ | ヒアルロン酸合成促進剤、HAS2mRNA発現促進剤、ヒアルロン酸合成促進作用を有する医薬品、食品又は化粧料、及び、HAS2mRNA発現促進作用を有する医薬品、食品又は化粧料 |
JP2015164901A (ja) * | 2014-02-28 | 2015-09-17 | 株式会社Aob慧央グループ | ヒアルロン酸合成促進剤、HAS2mRNA発現促進剤、ヒアルロン酸合成促進作用を有する医薬品、食品又は化粧料、及び、HAS2mRNA発現促進作用を有する医薬品、食品又は化粧料 |
Also Published As
Publication number | Publication date |
---|---|
US20080262080A1 (en) | 2008-10-23 |
JPWO2006038656A1 (ja) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rosenkranz et al. | Induction of regulatory T cells in Th1-/Th17-driven experimental autoimmune encephalomyelitis by zinc administration | |
RU2423139C2 (ru) | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ Actinidia, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
JPWO2017047769A1 (ja) | トール様受容体7またはトール様受容体9の活性化阻害剤 | |
Iwaki et al. | Tryptanthrin inhibits Th2 development, and IgE-mediated degranulation and IL-4 production by rat basophilic leukemia RBL-2H3 cells | |
Wang et al. | Secoisolariciresinol diglucoside suppresses Dextran sulfate sodium salt-induced colitis through inhibiting NLRP1 inflammasome | |
WO2006038656A1 (ja) | アレルギー抑制剤 | |
TW202139980A (zh) | 以大麻二酚及依維莫司(everolimus)治療結節性硬化症之方法 | |
JP7060500B2 (ja) | 薬学的組成物の製造方法、医薬部外品組成物の製造方法、飼料組成物の製造方法、及び、飲用水添加剤の製造方法 | |
Li et al. | Maternal folic acid deficiency stimulates neural cell apoptosis via miR-34a associated with Bcl-2 in the rat foetal brain | |
Chiu et al. | Catalpol exerts antiallergic effects in IgE/ovalbumin-activated mast cells and a murine model of ovalbumin-induced allergic asthma | |
JP6081025B2 (ja) | モノアセチルジアシルグリセロール化合物を有効成分として含有する喘息の予防または治療用組成物 | |
US20160067270A1 (en) | Use of ginsenoside f2 for prophylaxis and treatment of liver disease | |
Matsui et al. | Effects of anti-allergy drugs on Th1 cell and Th2 cell development mediated by Langerhans cells | |
Ho, Deh-Ming Chang, Hen-Yih Shiau, Chen-Hung Chen, Tsai-Yuan Hsieh, Yu-Lin Hsu, Chih-Shung Wong, Jenn-Haung Lai | Aspirin differentially regulates endotoxin-induced IL-12 and TNF-α production in human dendritic cells | |
Hao et al. | Saikosaponin-d inhibits β-conglycinin induced activation of rat basophilic leukemia-2H3 cells | |
JP2023089077A (ja) | N-アセチル又はn-アシルアミノ酸を含むアトピー又は痒み症治療用組成物 | |
JP6000206B2 (ja) | 抗アレルギー用経口組成物 | |
Li et al. | B cells from old mice induce the generation of inflammatory T cells through metabolic pathways | |
JP6112920B2 (ja) | Nrf2活性化剤 | |
JP7193121B2 (ja) | マクロファージの機能低下抑制剤 | |
WO2012144501A1 (ja) | 抗アレルギー物質、抗アレルギー剤及び食品 | |
Minns et al. | A novel triterpenoid induces transforming growth factor β production by intraepithelial lymphocytes to prevent ileitis | |
WO2019112031A1 (ja) | 全身性強皮症治療剤 | |
JP6113325B2 (ja) | 抗アレルギー用経口組成物 | |
JP6639162B2 (ja) | レンコン節部の抽出物を含有する抗アレルギー剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006539318 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05790445 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11664622 Country of ref document: US |